Amphion Innovations (AMP)


LSE:AMP: Director/PDMR Shareholding

Amphion Innovations

09 Dec 2016 15:50:25

Amphion Innovations

RNS Number : 4898R
Amphion Innovations PLC
09 December 2016

Amphion Innovations plc

 ("Amphion" or "the Company")

Directors Dealings

London and New York, 9 December 2016 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 8 December 2016 it granted options over ordinary shares in the Company ("Options") to certain of its Directors as follows:



Strike Price


Richard Mansell-Jones


2.38 pence

Monthly over a 36 month period

Richard Mansell-Jones


2.38 pence

Monthly over a 12 month period

Paul Kennedy


2.38 pence

Monthly over a 12 month period

Miroslaw Izienicki


2.38 pence

Monthly over a 12 month period


All Options commence vesting backdated from 1 August 2016. 


The strike price is based on the closing price on 8 December 2016, and the Options are exercisable on the date of vesting.  Authority for the allotment of ordinary shares under the Share Option Scheme has already been given by the Shareholders in general meeting.


For further information please contact:


Amphion Innovations
Charlie Morgan
+1 212 210 6224

Yellow Jersey PR

Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker) 
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6625

Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502


About Amphion Innovations plc


Amphion Innovations is a developer of medical, life science and technology businesses.


We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.


On the web: 


This information is provided by RNS
The company news service from the London Stock Exchange